By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Medivation, Inc. 

525 Market Street
36th Floor
San Francisco  California  94105  U.S.A.
Phone: 415-543-3470 Fax: 415-543-3411


Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial.

For more information, please visit us at

Key Statistics

Ownership: Public

Web Site: Medivation
Employees: 18
Symbol: MDVN



Company News
Medivation (MDVN) Announces Participation At Upcoming Investor Conference 11/10/2015 1:05:36 PM
Medivation (MDVN) Reports Third Quarter 2015 Financial Results 11/9/2015 2:42:55 PM
Medivation (MDVN) Announces Third Quarter 2015 Financial Results Teleconference On November 5, 2015 10/27/2015 12:54:56 PM
Medivation (MDVN) CMO to Retire in October, Replacement Named 9/30/2015 6:10:23 AM
Medivation (MDVN) Release: Updated Enzalutamide Data In Triple-Negative Breast Cancer Presented At The 2015 European Cancer Congress 9/29/2015 1:13:19 PM
Medivation (MDVN) Effects A Stock Dividend On Its Common Stock 9/18/2015 11:23:59 AM
Medivation (MDVN) Announces Participation At Upcoming Investor Conference 9/8/2015 12:43:57 PM
Medivation (MDVN) To Expand Global Oncology Franchise With The Acquisition Of All Worldwide Rights To Talazoparib (BMN 673), A Potent PARP Inhibitor, From BioMarin (BMRN) 8/24/2015 10:07:35 AM
BioMarin (BMRN) Sells Phase III Breast Cancer Drug to Medivation (MDVN) for $570 Million 8/24/2015 6:17:15 AM
Medivation, Inc. (MDVN) Reports Second Quarter 2015 Financial Results 8/7/2015 11:01:15 AM